Version 1
: Received: 20 February 2024 / Approved: 21 February 2024 / Online: 21 February 2024 (11:38:35 CET)
How to cite:
Stewen, K.; Miehle, S.; Weigmann, H.; Schwab, R. Real-World Effects of a Hyoscine Butylbromide plus Paracetamol Combination in Women with Dysmenorrhea: A Patient Survey. Preprints2024, 2024021178. https://doi.org/10.20944/preprints202402.1178.v1
Stewen, K.; Miehle, S.; Weigmann, H.; Schwab, R. Real-World Effects of a Hyoscine Butylbromide plus Paracetamol Combination in Women with Dysmenorrhea: A Patient Survey. Preprints 2024, 2024021178. https://doi.org/10.20944/preprints202402.1178.v1
Stewen, K.; Miehle, S.; Weigmann, H.; Schwab, R. Real-World Effects of a Hyoscine Butylbromide plus Paracetamol Combination in Women with Dysmenorrhea: A Patient Survey. Preprints2024, 2024021178. https://doi.org/10.20944/preprints202402.1178.v1
APA Style
Stewen, K., Miehle, S., Weigmann, H., & Schwab, R. (2024). Real-World Effects of a Hyoscine Butylbromide plus Paracetamol Combination in Women with Dysmenorrhea: A Patient Survey. Preprints. https://doi.org/10.20944/preprints202402.1178.v1
Chicago/Turabian Style
Stewen, K., Harald Weigmann and Roxana Schwab. 2024 "Real-World Effects of a Hyoscine Butylbromide plus Paracetamol Combination in Women with Dysmenorrhea: A Patient Survey" Preprints. https://doi.org/10.20944/preprints202402.1178.v1
Abstract
Dysmenorrhea symptoms are frequent and often self-treated using non-prescription medicines. To further characterize women with dysmenorrhea using a combination of hyoscine butylbromide and paracetamol (PLUS) for self-management of their complaints, we performed a secondary analysis of a published pharmacy-based patient survey. 314 women (mean age 32.3 years) with dysmenorrhea reported a pain and cramps intensity of 7.45 ± 2.13 on a 0-10 Likert scale, which was reduced to 2.86 ± 1.81 upon treatment. Associated impairments of work/daily chores, leisure activities, and sleep were improved by 64.6%, 62.2% and 70.4%, respectively. The onset of symptom relief was within 60 min in 84.7%. Tolerability was rated as very good or good by 97.2%. These findings confirm the efficacy and tolerability data on PLUS from randomized controlled trials in a larger group of women conducting self-management of their dysmenorrhea.
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
